Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory.
Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Mendoza T, et al. Among authors: altan m. J Immunother Cancer. 2020 Oct;8(2):e000931. doi: 10.1136/jitc-2020-000931. J Immunother Cancer. 2020. PMID: 33097611 Free PMC article.
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis.
Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y. Abu-Sbeih H, et al. Among authors: altan m. J Immunother Cancer. 2019 Apr 2;7(1):93. doi: 10.1186/s40425-019-0577-1. J Immunother Cancer. 2019. PMID: 30940209 Free PMC article.
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.
Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW. Menon H, et al. Among authors: altan m. J Immunother Cancer. 2019 Sep 4;7(1):237. doi: 10.1186/s40425-019-0718-6. J Immunother Cancer. 2019. PMID: 31484556 Free PMC article.
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.
Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Welsh JW, et al. Among authors: altan m. J Thorac Oncol. 2020 Feb;15(2):266-273. doi: 10.1016/j.jtho.2019.10.001. Epub 2019 Oct 9. J Thorac Oncol. 2020. PMID: 31605794 Free article. Clinical Trial.
Immune-Related Adverse Events: Pneumonitis.
Zhong L, Altan M, Shannon VR, Sheshadri A. Zhong L, et al. Among authors: altan m. Adv Exp Med Biol. 2020;1244:255-269. doi: 10.1007/978-3-030-41008-7_13. Adv Exp Med Biol. 2020. PMID: 32301020 Free PMC article. Review.
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Alessi JV, Ricciuti B, Jiménez-Aguilar E, Hong F, Wei Z, Nishino M, Plodkowski AJ, Sawan P, Luo J, Rizvi H, Carter BW, Heymach JV, Altan M, Hellmann M, Awad M. Alessi JV, et al. Among authors: altan m. J Immunother Cancer. 2020 Aug;8(2):e001007. doi: 10.1136/jitc-2020-001007. J Immunother Cancer. 2020. PMID: 32753547 Free PMC article.
193 results